Sacituzumab Govitecan Achieves a 29 Percent Objective Response Rate in 35 Patients With Advanced Urothelial Cancer Who Failed Prior Platinum-Based Regimens and Immunotherapy
Future Steps Include Discussing Registrational Pathways with the FDA
Collaboration with Roche will Combine Sacituzumab Govitecan with Atezolizumab (Tecentriq®) in Patients with Previously-Untreated Metastatic Triple-Negative Breast Cancer (mTNBC)
Announcement of Phase 3 Study of Sacituzumab Govitecan in the Curative Setting of Breast Cancer In Conjunction with The German Breast Group
Resubmission Timeline of the mTNBC BLA Revised for Late November or Early December
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.